خون کا کینسر (AML leukaemia)
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
کہاں جانا ہے
اس ٹرائل کے لیے انڈیا میں 11 ہسپتال مریض لے رہے ہیں۔
رجسٹری کی سمری (ٹیکنیکل)
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo standard induction therapy, the current standard of care. This study will assess the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) being treated with of the combination of azacitidine and venetoclax, in India. The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing d…
سپانسر: AbbVie
ClinicalTrials.gov پر NCT07044687
رجسٹری میں آخری اپڈیٹ 11 ستمبر 2026 · ہم نے 20 اکتوبر 2026 کو پڑھا